bitglass

case study

# AMAG deploys Next-Gen CASB

Nathan McBride, VP IT of AMAG Pharmaceuticals, chose G Suite as the all cloud backbone for the company. G Suite offers a high performance productivity suite that is flexible and easy-to-use, allowing employees to rapidly adopt the tools needed to enhance productivity.

Combining BYOD and cloud meant that AMAG lost visibility and control of its data, risking security and compliance. Existing security solutions were blunt instruments that were not readily applicable to cloud apps. Plus they raised privacy concerns, since employees didn't want IT monitoring their personal cloud apps or mobile devices.

The Bitglass Cloud solution enables McBride to transparently secure cloud and mobile usage without deploying software on premises. Bitglass monitors and controls usage of cloud apps via contextual access-control policies by user, device, and geography. With its Omni multi-protocol proxies, Bitglass is able to secure all traffic from any endpoint without complex configuration. In addition, Bitglass protects AMAG files at access with its robust cloud DLP engine. Using configurable keyword regular expression rules, AMAG can even redact sensitive content on unmanaged mobile devices.

Bitglass also enables AMAG to selectively wipe corporate data from mobile devices without agents. Employees may use the native productivity clients on their personal device without the user experience hassles or privacy concerns of device management software. If a device is lost or compromised, AMAG can selectively wipe corporate data from the device and block continued access.

Bitglass delivers security for AMAG and privacy for employees.

**"Bitglass uniquely delivers a comprehensive security solution that automatically segments, tracks & secures sensitive data in cloud and mobile deployments without invading user privacy. Best of all, it's a zero- touch deployment."**
**—Nathan McBride, VP IT**

AMAG Pharmaceuticals, Inc., (NASDAQ: AMAG), engages in the development and commercialization of a therapeutic iron compound to treat iron de ciency anemia (IDA). The company's principal product includes Feraheme (injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company was founded in 1981 and is headquartered in Lexington, Massachusetts.